Cellics announced today that it has received a CARB-X Award of up to US$15 Million to develop a new treatment for sepsis caused by drug-resistant Gram-positive and Gram-negative bacteria. The award will allow Cellics to advance its highly versatile platform to treat not only sepsis but other conditions with unmet medical needs such as post CAR-T Cytokine Release Syndrome (CRS) and COVID-19.